ARTICLE | Clinical News

RMP-7 data

December 20, 1993 8:00 AM UTC

A Phase I trial in 10 patients showed that all five intravenous doses tested were well tolerated with no severe adverse effects, the company announced at the U.S.-Japan Symposium on Drug Delivery Systems in Maui. Of the five patients whose tumors could be imaged by contrast-enhanced MRI, three had a greater volume of distribution of the contrast agent, gadoteridol, after RMP-7 was given.

Baseline measure of tumor volume was followed a day later by 10, 20, 40, 80, and 160 ng/kg of RMP-7, with two patients receiving each dose. ...